Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.29 +3.15%
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
MSGM, SMID, VISL, More
EPS Growth %: +400.0%
Financial Fact:
NET LOSS FOR THE PERIOD: -7.29M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Royal Unibrew reports higher interim first-half profit as margins improve
- Yum! Brands (YUM) PT Lowered to $180 at Argus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
